Healthcare Industry News:  gene therapy  

Biopharmaceuticals Cardiology

 News Release - October 23, 2007

Genzyme Launches Cholestagel(R) in Europe

New Therapy Helps Lower Cholesterol in Primary Hypercholesterolemia Patients

CAMBRIDGE, Mass., Oct. 23 (HSMN NewsFeed) -- Genzyme Corp. (Nasdaq: GENZ ) today announced the launch of Cholestagel® (colesevelam hydrochloride), Genzyme's first commercially available cardiovascular product, in Europe. Cholestagel is a new, non-absorbed, cholesterol-lowering agent aimed at treating patients with primary hypercholesterolemia who cannot meet their targeted cholesterol levels with standard therapies alone.

"Cholestagel offers patients at high risk of life-threatening cardiovascular disease a new way to manage their cholesterol," said Genzyme Senior Vice President James A. Geraghty, who oversees the company's cardiovascular activities. "Most of these high-risk patients are seen at specialized treatment centers, and the launch of Cholestagel in Europe is consistent with our efforts to provide treatments for patients with serious unmet medical needs. We intend to do so with a small and highly-focused field organization that leverages Genzyme's existing country organizations."

Developed by Genzyme, Cholestagel is a polymer in tablet form that lowers LDL (or "bad") cholesterol. It can be taken in combination with other cholesterol-lowering medications, such as statins, or alone. When combined with various statins, fibrates or ezetimibe, current standard treatments for cholesterol control, Cholestagel was shown to have an additive LDL-cholesterol lowering effect in the range of 10 to 16 percent. A post-approval study launched in August 2007 by Genzyme aims to specifically demonstrate the efficacy of Cholestagel as an add-on therapy in patients with familial hypercholesterolemia (FH) -- an inherited disorder that causes exceptionally high levels of LDL-cholesterol -- who cannot reach their target LDL- cholesterol levels with a maximum regimen of statins and ezetimibe alone.

This double-blind, randomized "TRIPLE" study will involve 80 patients with FH enrolled in six European centers (including in the UK, Netherlands, Sweden and France) and preliminary results are expected in Q3 2008.

"Patients with genetic conditions like familial hypercholesterolemia are at particularly high risk of early coronary heart disease," said Dr. Anthony Wierzbicki, from London's St. Thomas' Hospital and a board member and chairman of the Medical Scientific and Research Committee of FH patient association 'Heart UK'. "Patients have to take multiple cholesterol-lowering therapies and yet still often require further cholesterol reduction to reach target lipid levels recommended for patients at risk of cardiovascular events. New non-systemic agents are a welcome addition for these patients to help them achieve these targets."

Unlike most other cholesterol-lowering treatments, Cholestagel is non- systemic, and therefore is not absorbed into the bloodstream. Cholestagel binds bile acids in the intestine, impeding their reabsorption. This process -- called bile acid sequestration -- results in an increased clearance of LDL cholesterol from the blood. Cholestagel is also well tolerated, with minimal gastrointestinal side effects similar to those seen in placebo, and has limited drug-interaction.

Colesevelam has been approved for use in the United States since 2000, where it is marketed by Daiichi Sankyo Inc. under the trade name WelChol®. Genzyme plans to launch Cholestagel in the United Kingdom, the Netherlands and the Scandinavian region this quarter, and in additional European countries next year. Genzyme also intends to pursue regulatory approvals for Cholestagel in Latin America, Canada, and the Asia Pacific region.

Genzyme has been conducting innovative research in the field of cardiovascular disease for several years. The company is currently running a Phase 2 gene therapy trial with the intention of forming new blood vessels to improve the flow of oxygen in the legs of patients with peripheral arterial disease.

About Primary Hypercholesterolemia

Primary hypercholesterolemia comprises a range of disorders in which LDL cholesterol blood levels are above normal (usually above 200mg/dl or 5mmol/l) due to a number of possible genetic mutations such as familial hypercholesterolemia, where patients inherit a gene that prevents them from metabolizing LDL cholesterol properly. These patients face a markedly increased risk of premature cardiovascular disease and CVD-related death. For more information about Cholestagel, please visit

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including statements about the timing and geographies of Cholestagel's launch, as well as statements concerning Genzyme's plans to seek regulatory approval for Cholestagel in additional geographies. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, the size of the market for the therapy in any particular geography, the sufficiency of reimbursement for the therapy in any particular geography; actions by governmental authorities related to Cholestagel, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme® and Cholestagel® are registered trademarks of Genzyme Corporation and WelChol® is a registered trademark of Daiichi Sankyo Inc. All rights reserved.

Genzyme's press releases and other company information are available at and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Source: Genzyme

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.